在线观看人与动牲交视频_夜夜高潮次次欢爽AV女_奇米在线视频观看_欧美精品七区_色悠久久综合网_少妇潮喷无码白浆水视频

加拿大Valeant Pharmaceuticals
Valeant生產用于治療皮膚和神經疾病的處方和非處方藥，現有員工大約2200人。

Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops and markets specialty pharmaceutical, branded generic and OTC products that make a meaningful difference in patients' lives. We are focused primarily on the neurology and dermatology therapeutic areas in the United States, Canada, and Australia markets, while operating branded generics businesses in Latin America and Europe. Based in Orange County, California, we employ approximately 2,300 people worldwide.

Throughout 2008, Valeant's new management team simplified and refocused our business strategy to concentrate on the company's strengths in the neurology and dermatology therapeutic areas. We plan to maximize our pipeline through strategic partnering to optimize our research and development assets and strengthen ongoing internal development capabilities. During the year, we made significant strides and divested our licensing rights in Argentina, the Asia Pacific region, Western and Eastern Europe, and the Middle East. Additionally, we signed an exclusive worldwide partnership agreement with GSK for retigabine, our Phase III compound. Valeant also entered into a join venture agreement with Meda AB to strengthen its presence in Canada, Mexico and Australia. In October 2008, we acquired Coria Laboratories, Ltd., and expanded our dermatology product portfolio with 17 prescription and OTC products. In November 2008, we acquired DermaTech, a dermatology company based in Australia with key products in retail and prescription brands. In December 2008, Valeant acquired Dow Pharmaceutical Sciences, Inc., a specialty pharmaceutical company that adds six compounds to our development pipeline and a recently FDA-approved product for acne, Acanya?, which we expect to launch in the first quarter of 2009.

At Valeant, we never lose sight of why we are in business - to improve the health and enhance the lives of our patients through innovative medicines and products.